# This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

> **NCT03449381** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 266 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BI 907828

## Key facts

- **NCT ID:** NCT03449381
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-20
- **Primary completion:** 2025-11-13
- **Final completion:** 2025-11-13
- **Target enrollment:** 266 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03449381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03449381, "This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03449381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*